Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

• Status: Completed
• Trial end date: 2017-08-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Enrollment on previous Amgen study 20030211 (NCT00078819)

Exclusion Criteria:

• Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept